KBRA Assigns Ratings to Sequoia Mortgage Trust 2023-3 (SEMT 2023-3)
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns ratings to 55 classes of mortgage pass-through certificates from Sequoia Mortgage…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns ratings to 55 classes of mortgage pass-through certificates from Sequoia Mortgage…
MARINA DEL REY, Calif.–(BUSINESS WIRE)–Rubicon Carbon, a next generation carbon solutions provider, and Freepoint Commodities…
Leadership Addition Strengthens Company’s Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE…
SEATTLE, Aug. 23, 2023 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc., a transformative immuno-oncology company creating…
New data showcases how rent reporting legislation is bridging the racial wealth gap HARLEM, N.Y.,…
BERLIN and NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) — Spryker, the leading composable commerce…
New Delhi, India, Aug 23, 2023 – (ACN Newswire) – As a state-owned energy company,…
LONDON, Aug 23, 2023 – (ACN Newswire) – French AI artist and polyhyphenate creative Agoria…
SEOUL, S.KOREA, Aug 23, 2023 – (ACN Newswire) – HFR, Inc. (KOSDAQ 230240), a leading…
NAIROBI, Kenya, Aug 23, 2023 – (ACN Newswire) – PT Pertamina (Persero) and its sub-holdings…
Standard AI will leverage Google Cloud’s AI tools to transform retail operations, elevate the in-store…
Predictions and Voice Intelligence Launches Drive Deeper, Actionable Understanding of Customers New Generative AI Tools…
TAIPEI, Taiwan–(BUSINESS WIRE)–CyberLink Corp. (5203.TW), a pioneer in AI and facial recognition technologies, today announced…
Portkey.ai is enabling tech teams to fast track the build and deployment of generative AI…
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside…
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside…
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the “Company”)…
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the “Company”)…
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after…
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after…